Veradermics (MANE.US) has submitted an application for a US stock market IPO with the intention of paving the way for the commercialization of oral hair growth medication.

Biotechnology company Veradermics (MANE.US) has officially filed for an initial public offering, aiming to provide funding support for the commercialization of its oral hair growth medicine. According to documents submitted to the US Securities and Exchange Commission on Friday, Veradermics is developing an oral non-hormonal therapy for male and female androgenetic alopecia (also known as "pattern hair loss"). The company stated that about 80 million people in the US are affected by this condition. The company is led by co-founders and dermatologists Redmond Mann and Tim Durso. The documents show that in preparation for submitting late-stage trial data to the US Food and Drug Administration for market approval, the company has begun patient identification, doctor education, and plans to launch product marketing directly to consumers. Veradermics will disclose specific terms of the offering in subsequent filings, followed by the start of stock promotion. The IPO is planned to launch as soon as later this month. Previously, Veradermics completed a $150 million Series C financing in October last year. The round was led by SR One, with new investors Viking Global Investors, Marshall Wace, and Invus, as well as existing investors Longitude Capital and Suvretta Capital Management participating in the round. Jefferies Financial Group Inc., Leerink Partners, Citigroup, and Cantor Fitzgerald are serving as the lead underwriters for the offering. The company plans to list on the New York Stock Exchange, with the stock symbol expected to be "MANE".